Translate Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber/Boston Children’s assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a for a discussion about your care.
Displaying 1-10 of 77 results matching:
Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception in 2007, earning more #1 rankings than any other program.
U.S. News & World Report has recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #3 pediatric cancer program in the nation in its 2025-2026 Best Children's Hospitals report.
David Williams, MD, has been awarded the Henry M. Stratton Medal for clinical science by the American Society of Hematology, one of the highest distinctions for excellence in the hematology field.
She will also serve as Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital
Dana-Farber/Boston Children’s is honored to have 11 faculty members named part of Boston Magazine’s "Top Doctors" for 2025.
U.S. News & World Report has again recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation in its 2024-25 Best Children's Hospitals report.
Dana-Farber/Boston Children’s Cancer and Blood Disorder Center is happy to announce three research fellows have been named as part of the Inaugural class of Damon Runyon–St. Jude Pediatric Cancer Research Fellows.
Dana-Farber/Boston Children’s is honored to have 12 faculty members named part of Boston magazine’s “Top Doctors” for 2024.
Lisa Diller, MD, Chief Medical Officer at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, has been named an Innovator in Healthcare for Research by the Boston Business Journal.
Stuart H. Orkin, MD has been awarded the third Elaine Redding Brinster Prize in Science or Medicine for his landmark discoveries of the molecular basis of blood disorders and using the basic science findings for therapeutic approaches